Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma

被引:14
|
作者
Wehle, MJ
Lisson, SW
Buskirk, SJ
Broderick, GA
Young, PR
Igel, TC
机构
[1] Mayo Clin, Coll Med, Dept Urol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Coll Med, Dept Radiat Oncol, Jacksonville, FL 32224 USA
关键词
D O I
10.4065/79.3.314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate whether preoperative genitourinary variables in patients undergoing brachytherapy for localized prostate adenocarcinoma could predict postoperative genitourinary tract morbidity. Patients and Methods: We retrospectively reviewed medical records of 105 men who received either iodine 125. or palladium 103 radioactive seed implants with or without external beam radiotherapy or hormone blockade from January 1, 1998, through December 31, 2000, at the Mayo Clinic in Jacksonville, Fla. Patients with one or more of the following were classified as having a high risk of postoperative genitourinary tract morbidity: American Urological Association symptom scores greater than 15, maximum urinary flow rate less than 10 mL/s, postvoid residual urinary volume greater than 100 mL, or prostate volume greater than 40 cm(3). Of the 105 men, 59 (56%) were classified as high risk and 46 (44%) as low risk. Mean follow-up after brachytherapy was 23.6 months. Modified Radiation Therapy Oncology Group scores were used to assess postoperative genitourinary tract morbidity. The term significant genitourinary tract morbidity was applied to patients with a Radiation Therapy Oncology Group grade of 3 or 4 after at least 6 months of follow-up. Results: Significant morbidity occurred in 37% of high-risk vs 15% of low-risk patients (P=.006). In high-risk patients, transurethral resection or incision of the prostate was required in 5 patients, urethral dilation in 4, direct-vision internal urethrotomy in 1, and placement of a suprapubic catheter in 1. In low-risk patients, transurethral incision of the prostate was required in only 1 patient. Urinary flow rate was a significant individual predictor of postoperative morbidity (P=.03). Conclusions: A combination of urinary flow rate, prostate volume, postvoid residual urinary volume, and American Urological Association symptom score can help identify patients with underlying voiding dysfunction. Urinary flow rate was a statistically significant predictor of genitourinary tract morbidity after brachytherapy for localized prostate adenocarcinoma. Patients and physicians should consider these factors before a patient decides to undergo brachytherapy.
引用
收藏
页码:314 / 317
页数:4
相关论文
共 50 条
  • [21] Radiation-Induced Leiomyosarcoma of the Prostate after Brachytherapy for Prostatic Adenocarcinoma
    Horiguchi, Hiroto
    Takada, Kohichi
    Kamihara, Yusuke
    Ibata, Soushi
    Iyama, Satoshi
    Sato, Tsutomu
    Hayashi, Tsuyoshi
    Miyanishi, Koji
    Sato, Yasushi
    Takimoto, Rishu
    Kobune, Masayoshi
    Kobayashib, Ko
    Hirayama, Yasuo
    Masumori, Naoya
    Hasegawa, Tadashi
    Kato, Junji
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 565 - 570
  • [22] Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
    Kanai, Kunimitsu
    Nakashima, Jun
    Sugawara, Akitomo
    Shigematsu, Naoyuki
    Nagata, Hirohiko
    Kikuchi, Eiji
    Miyajima, Akira
    Nakagawa, Ken
    Kubo, Atsushi
    Oya, Mototsugu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (06) : 502 - 506
  • [23] Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
    Kunimitsu Kanai
    Jun Nakashima
    Akitomo Sugawara
    Naoyuki Shigematsu
    Hirohiko Nagata
    Eiji Kikuchi
    Akira Miyajima
    Ken Nakagawa
    Atsushi Kubo
    Mototsugu Oya
    International Journal of Clinical Oncology, 2009, 14 : 502 - 506
  • [24] Predictive Factors for Urinary Morbidity after I-125 Prostate Brachytherapy
    Senzaki, T.
    Fukumori, T.
    Komori, M.
    Yamamoto, Y.
    Yamaguchi, K.
    Nakatsuji, H.
    Izaki, H.
    Takahashi, M.
    Kanayama, H.
    UROLOGY, 2012, 80 (03) : S292 - S292
  • [25] The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer
    Blaivas, Jerry G.
    Weiss, Jeffrey P.
    Jones, Mark
    BJU INTERNATIONAL, 2006, 98 (06) : 1233 - 1237
  • [26] Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma
    Guarneri, Alessia
    Botticella, Angela
    Ragona, Riccardo
    Filippi, Andrea Riccardo
    Munoz, Fernando
    Casetta, Giovanni
    Gontero, Paolo
    Tizzani, Alessandro
    Ricardi, Umberto
    WORLD JOURNAL OF UROLOGY, 2013, 31 (02) : 411 - 415
  • [27] Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma
    Alessia Guarneri
    Angela Botticella
    Riccardo Ragona
    Andrea Riccardo Filippi
    Fernando Munoz
    Giovanni Casetta
    Paolo Gontero
    Alessandro Tizzani
    Umberto Ricardi
    World Journal of Urology, 2013, 31 : 411 - 415
  • [28] Minimizing prostate brachytherapy-related morbidity
    Merrick, GS
    Wallner, KE
    Butler, WM
    UROLOGY, 2003, 62 (05) : 786 - 792
  • [29] Editorial Comment to Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy
    Mabjeesh, Nicola J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (12) : 1090 - 1090
  • [30] Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy
    Gutman, S
    Merrick, GS
    Butler, WM
    Wallner, KE
    Allen, Z
    Galbreath, RW
    Adamovich, E
    BJU INTERNATIONAL, 2006, 97 (01) : 62 - 68